Eribulin versus S-1 as first- or second- line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomized controlled trial
Eribulin versus S-1 as first- or second- line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomized controlled trial
复制标题
艾日布林与 S-1 作为一线或二线化疗来评估 HER2 阴性转移性乳腺癌的健康相关生活质量和总体生存率（RESQ 研究）：一项非劣效性随机对照试验
DOI：
--
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Takahashi M
中科院分区：
文献类型：
--
作者：
Kikawa Y;Kashiwabara K;Taira N;Iwatani T; Shimozuma K;Ohtani S; Yoshinami T;Watanabe J;Kashiwaba M; Watanabe K-i;Kitada M; Sakaguchi K;Tanabe Y; Aihara T;Mukai H; Takahashi M
